

Express Mail No.: EL 501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hong Jin et al.

Confirmation No.: 1768

Application No.: 09/923,070

AND VACCINES

Group Art Unit: 1648

Filed: August 6, 2001

Examiner: Lucas, Zachariah

For: RECOMBINANT RSV EXPRESSION SYSTEMS Attorney Docket No.: 7682-059-999

RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 C.F.R. § 1.142 PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

In response to the Office Action mailed November 4, 2002, please enter the following amendments and consider the remarks below. Applicants submit concurrently herewith: (1) an Amendment Fee Transmittal Sheet (in duplicate); (2) a Petition for Extension of Time under 37 C.F.R. § 136(a) for four months from December 4, 2002 to and including April 4, 2003; (3) a list of the claims as they will be pending upon entry of the present amendment (Exhibit A); (4) a marked-up version of the amended paragraph on page 1 to show changes made (Exhibit B); and (5) a copy of an Amendment, filed September 5, 2002 in the co-pending parent application of the present application, U.S. Application No. 09/161,122 with stamped return receipt postcard certifying receipt by the Patent and Trademark Office (Exhibit C).

IN THE CLAIMS

Please cancel claims 1-24 without prejudice.

Please add the following new claims:

25. (new) A vaccine comprising a respiratory syncytial virus (RSV) the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of RSV, wherein the genome contains sequences heterologous to